- Ian H Kunkler, consultant in clinical oncology1
- 1Edinburgh Cancer Centre, Edinburgh EH4 2XU, UK
- i.kunkler{at}ed.ac.uk
The National Institute for Health and Care Excellence’s decision not to recommend abiaterone for men with advanced prostate cancer before chemotherapy, which was based on inadequate evidence of cost effectiveness, illustrates a common challenge for novel anticancer agents.1 Tension exists between the NHS obtaining value for money, patients obtaining access to new drugs, and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.